Cargando…
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)
This study evaluates the overall survival and disease free survival of melanoma patients that were treated with an autologous melanoma cell vaccine, administered as a post-operative adjuvant. Included are 43 patients with totally resected metastatic melanoma (28-AJCC stage III, 15-AJCC stage IV), wi...
Autores principales: | Lotem, M, Peretz, T, Drize, O, Gimmon, Z, EL, D Ad, Weitzen, R, Goldberg, H, David, I Ben, Prus, D, Hamburger, T, Shiloni, E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746603/ https://www.ncbi.nlm.nih.gov/pubmed/12085200 http://dx.doi.org/10.1038/sj.bjc.6600251 |
Ejemplares similares
-
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004) -
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
por: Lotem, Michal, et al.
Publicado: (2016) -
Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients
por: Mactier, Swetlana, et al.
Publicado: (2014) -
A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
por: Biswas, S, et al.
Publicado: (2008) -
A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden
por: Isaksson, Karolin, et al.
Publicado: (2019)